 By John Vandermosten, CFA NASDAQ:DYAI On July 8, 2020, Dyadic NASDAQ:DYAI announced the successful addition of two, fully funded collaborations with global animal health companies to study whether it is feasible for Dyadics fungal protein expression platform, C1, to produce desired therapeutic proteins. While management has not explicitly disclosed the partners, they have announced that four 